Dasatinib

1. Dasatinib lowers the risk of Parkinson's disease in humans (RR = 0.53, 95% CI: 0.35-0.82).

   Humansadjusted for age, sex, race, smoking, and healthcare utilization

   Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 27 Aug 2026

Parkinson's disease →